DOI: https://doi.org/10.22141/2224-0586.3.58.2014.83274

Anti-B-Cell Therapy — a New Direction in the Treatment of ANCA-Associated Systemic Vasculitis

O.B. Yaremenko, L.B. Petelitskaya

Abstract


.

References


Насонов Е.Л. Васкулиты и васкулопатии / Е.Л. Насонов, А.А. Баранов, Н.П. Шилкина. — Ярославль: Верхняя Волга, 1999. — С. 611.

Яременко О.Б. Ефективність і переносимість імунобіологічної терапії у пацієнтів із ревматоїдним артритом / О.Б. Яременко, О.І. Івашківський, Д.Л. Федьков // Укр. ревматол. журн. — 2012. — № 1 (47). — С. 76-82.

Яременко О.Б. Иммунобиологическая терапия при ревматоидном артрите: новые технологии — новые возможности / О.Б. Яременко // Здоров’я України. — 2009. — № 10. — С. 57-59.

Яременко О.Б. Ревматоидный артрит: эра иммунобиологической терапии // Науковий вісник Національного медичного університету імені О.О. Богомольця. — 2009. — № 25. — С. 325-336.

Bartolucci P. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients / P. Bartolucci, J. Ramanoelina, P. Cohen, A. Mahr, P. Godmer, C. Le Hello et al. // Rheumatology (Oxf). — 2002. — Vol. 1170. — P. 1126-1132.

Brihaye B. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: a study on 8 patients / B. Brihaye, A. Aouba, C. Pagnoux et al. // Clin. Exp. Rheumatol. — 2007. — Vol. 120. — P. 23-27.

Booth A. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis / A. Booth, L. Harper, T. Hammad, P. Bacon, M. Griffith, J. Levy et al. // J. Am. Soc. Nephrol. — 2004. — Vol. 820. — P. 717-721.

Booth A.D. Safety and efficacy of TNFalpha blockade in relapsing vasculitis / A.D. Booth, H.J. Jefferson, W. Ayliffe, P.A. Andrews, D.R. Jayne // Ann. Rheum. Dis. — 2002. — Vol. 720. — P. 559.

Brihaye B. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: a study on 10 patients / B. Brihaye, A. Aouba, C. Pagnoux et al. // Clin. Exp. Rheumatol. — 2009. — Vol. 134. — P. 28-30.

Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab / P. Eriksson // J. Intern. Med. — 2005. — Vol. 650. — P. 540-548.

Falk R.J. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro / R.J. Falk, R.S. Terrell, L.A. Charles, J.C. Jennette // Proc. Natl. Acad. Sci. — 1990. — Vol. 87. — P. 4115-4119.

Falk R.J. Granulomatosis with Polyangiitis (Wegener’s): An alternative name for Wegener’s Granulomatosis / R.J. Falk, W.L. Gross, L. Guillevin, G.S. Hoffman et al. // Arthritis. Rheum. — 2011. — Vol. 1120. — P. 863-864.

Ferraro A.J. Effective therapeutic use of rituximab in refractory Wegener’s granulomatosis / A.J. Ferraro, C.J. Day, M.T. Drayson, C.O. Savage // Nephrol. Dial. Transpl. — 2005. — Vol. 700. — P. 622-625.

Flossman O. Long term patient survival in ANCA associated vasculitis / O. Flossman, A. Berden, K. de Groot et al. // Ann. Rheum. Dis. — 2011. — Vol. 750. — P. 488-494.

Fujimoto S. Comparison of the epidemiology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis between Japan and UK / S. Fujimoto, R.A. Watts, S. Kobayashi, K. Suzuki, D.R.W. Jayne, G.D.I. Scott, H. Hashimoto, H. Nunoi // Rheumatology. — 2011. — Vol. 2010. — P. 1916-1920.

Gross W.L. Immunopathology and newtherapeutic considerations in ANCA-associated vasculitides / Gross W.L. // Autoimmun. Rev. — 2004. — Vol. 120. — P. 47-48.

Harper L. Pathogenesis of ANCA-associated systemic vasculitis / L. Harper, С. Savage // J. Pathol. — 2000. — Vol. 190. — P. 149-59.

Holle J.U. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations / J.U. Holle, C. Dubrau, K. Herlyn et al. // Ann. Rheum. Dis. — 2012. — Vol. 71. — P. 327-333.

Jennette J.C. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides / J.C. Jennette, R.J. Falk, P.A. Bacon et al. // Arthritis & Rheumatism. — 2013. — Vol. 65. — P. 1-11.

Jones R.B. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis / R.B. Jones, J.W. Tervaert, T. Hauser et al. // N. Engl. J. Med. — 2010. — Vol. 363. — P. 211-220.

Keogh K.A. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis / K.A. Keogh, M.E. Wylam, J.H. Stone, U. Specks // Arthritis Rheum. — 2005. — Vol. 352. — P. 262-268.

Keogh K.A. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial / K.A. Keogh, S.R. Ytterberg, F.C. Fervenza et al. // Am. J. Respir. Crit. Care Med. — 2006. — Vol. 193. — P. 180-187.

Lamprecht P. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis / P. Lamprecht, J. Voswinkel, T. Lilienthal, B. Nolle, M. Heller, W.L. Gross et al. // Rheumatology (Oxf). — 2002. — Vol. 1500. — P. 1303-1307.

Laurino S. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement / S. Laurino, A. Chaudhry, A. Booth, G. Conte, D. Jayne // Nephrol. Dial. Transpl. — 2010. — Vol. 360. — P. 307-314.

Maloney D. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma / D.G. Maloney, A.J. Grillo-Lopez, C.A. White et al. // Blood. — 1997. — Vol. 3200. — P. 2188-2195.

Guerry M.-J.C.J. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis / P. Brogan et al. // Rheumatology (Oxford). — 2011. — Vol. 680. — P. 634-643.

Morgan M.D. Addition of infliximab to standard therapy for ANCA-associated vasculitis / M.D. Morgan, M.T. Drayson, C.O. Savage, L. Harper // Nephron. Clin. Pract. — 2011. — Vol. 117. — P. 89-97.

Mukhtyar C. EULAR recommendations for the management of primary small and medium vasculitis / C. Mukhtyar, L. Guillevin, M. Cid et al. // Ann. Rheum. Dis. — 2009. — Vol. 750. — P. 307-310.

Mukhtyar C. Modification and validation of the Birmingham vasculitis activity score (Version 3) / C. Mukhtyar, R. Lee, D. Brown et al. // Ann. Rheum. Dis. — 2009. — Vol. 68. — P. 1827-1832.

Ntatsaki E. Epidemiology of ANCA-associated vasculitis / E. Ntatsaki, R.A. Watts, D.G. Scott // Rheum. Dis. Clin. North Am. — 2010. — Vol. 565. — P. 447-461.

Omdal R. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response / R. Omdal, K. Wildhagen, T. Hansen, R. Gunnarsson, G. Kristoffersen // Scand. J. Rheumatol. — 2005. — Vol. 285. — P. 229-232.

Savage C.O. Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis / C.O. Savage // Clin. Exp. Immunol. — 2011. — Vol. 164. — P. 23-26.

Shlomchik M.J. From T to B and back again: positive feedback in systemic autoimmune disease / M.J. Shlomchik, J.E. Craft, M.J. Mamula // Nat. Rev. Immunol. — 2001. — Vol. 200. — P. 147-153.

Smith K.G. et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re- treatment / K.G. Smith, R.B. Jones, S.M. Burns, D.R. Jayne // Arthritis Rheum. — 2006. — Vol. 3000. — P. 2970-2982.

Stasi R. Long-term observations of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab / R. Stasi, E. Stipa, G. Del Poeta, S. Amadori, A.C. Newland // Rheumatology (Oxf). — 2006. — Vol. 1500. — P. 1432-1436.

Stone J.H. Etanercept plus standard therapy for Wegener’s granulomatosis / Stone J.H. et al. The Wegener’s Granulomatosis Etanercept (WGET) Research Group // N. Engl. J. Med. — 2005. — Vol. 380. — P. 351-361.

Stone J.H. Rituximab versus cyclophosphamide for ANCA-associated vasculitis / J.H. Stone, P.A. Merkel, R. Spiera et al. // N. Engl. J. Med. — 2010. — Vol. 363. — P. 221-232.

Tamura N. Two cases of refractory Wegener’s granulomatosis successfully treated with rituximab / N. Tamura, R. Matsudaira, M. Hirashima et al. // Intern. Med. — 2007. — Vol. 46. — P. 40.

Voswinkel J. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions / J. Voswinkel, A. Mueller, J.A. Kraemer, P. Lamprecht, K. Herlyn, K. Holl-Ulrich, A.C. Feller, S. Pitann, A. Gause, W.L. Gross // Ann. Rheum. Dis. — 2006. — Vol. 1200. — P. 859-864.

Watts R.A. Epidemiology of vasculitis / R.A. Watts, D.G.I. Scott // Vasculitis. 2nd ed. — Oxford: Oxford University Press, 2008. — P. 7-22.

Wilde B. New pathophysiological insights and treatment of ANCA-associated vasculitis / B. Wilde, P. Paassen, O. Witzke, J. Tervaert // Kidney International. — 2011. — Vol. 59. — P. 599-612.




Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта